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Rnumber of important studies were reported in 2006 in
he area of cardiac electrophysiology. It is obviously
mpossible to discuss all important contributions, hence we
mphasize those that we feel are most apt to break new
round relative to basic observations or clinical care.
olecular-Genetic Arrhythmia Syndromes
number of studies of genetic and molecular effects on
rrhythmogenesis are noteworthy.
ong QT syndrome (LQTS). Despite the great advances
n our understanding of the role of channel disorders as
auses for the LQTS, at present in at least 25% of these
atients no genetic defect has been established. The iden-
ified mutant genes are responsible for coding either the
lpha (membrane spanning) or rarely the beta subunits of
on channels. A very rare cause of the LQTS, for example,
s caused by an abnormality in ANK2, which encodes
nkyrin-B, a protein thought to be involved in the traffick-
ng of Na and Ca channels to the cell membrane. It is
he first example of a nonchannel protein disorder that
ffects channel function. The proteins that make up the ion
hannel are formed within the endoplasmic reticulum and
oved (or trafficked) to the appropriate location in the
yocardial cell membrane. Hence a channel disorder might
e manifest not because of any intrinsic defect in the
akeup of a specific ion channel, but because of an inability
o transport the protein to the appropriate site on the
embrane.
aveolin-3 mutations and LQTS. More recently, atten-
ion has been focused on the caveolae, which are microdo-
ains found in the sarcolemma and serve both as scaffolding
or ion channels as well as in signal transduction (beta-2
drenergic pathway).
In a recent very important study, Vatta et al. (1) analyzed
lood from 905 unrelated patients who underwent genetic
esting for LQTS. They also showed that caveolin-3 colo-
alizes with the voltage-gated Na channel (h Nav 1.5) in
uman myocardium and identified 4 novel mutations in
AV-3, which encodes caveolin-3 protein.
rom the *Section of Cardiac Electrophysiology, University of California San
rancisco, San Francisco, California; and the †Veterans Affairs Medical Center, San
rancisco, California.w
Manuscript received December 15, 2006; revised manuscript received February 9,
007, accepted February 12, 2007.The CAV-3 mutations were associated with a 2- to 3-fold
ncrease in late sodium current. The investigators conclude
hat the CAV-3 mutants simulated the LQT3 abnormality,
hich has been associated with mutations in the SCN5A
ene (which encodes the Na channel). The electrocardio-
ram (ECG) shown in their report, however, differed from
lassic examples of patients with LQT3. The importance of
hese observations likely extends beyond the described
ffects on the late Na current because a number of cardiac
on channels have been found to localize in the caveolae.
his opens up the potential for further exploring the role of
onchannel proteins as causes for disturbances in ion
hannel function.
rugada syndrome. There were several important new
ndings for patients with Brugada syndrome. This syn-
rome is characterized by a form of right bundle branch
attern with ST elevation and coved T waves in precordial
eads V1 to V3 (type I Brugada pattern) (2) (Fig. 1). This
attern may be associated with lethal ventricular arrhyth-
ias. The type II Brugada pattern shows a saddleback
onfiguration between the end of the QRS and the T-wave.
he saddleback pattern (type II) is thought to be less
pecific for this syndrome.
Current evidence suggests that this syndrome is caused by
channelopathy, and approximately 20% to 30% of indi-
iduals are found to have mutations in the gene that encodes
he alpha subunit of the Na channel (SCN5A) (3). Our
urrent understanding is that the Brugada pattern is caused
y abnormalities in the balance of ionic current flowing
uring phase 1 of the action potential. The currents that are
ctive during this phase involve the inward Na and Ca
urrents as opposed to the outward K currents, largely Ito
transient outward K current). Predominance of the in-
ard current in the epicardium would produce a gradient
rom endocardium to epicardium resulting in a prominent
otch or J-wave (4,5).
The right ventricular (RV) epicardium harbors a more
ntensive Ito current than the left ventricular myocardium.
ence, intensification of the outward currents or loss of the
nward currents produce the J-wave and ST-segment eleva-
ion in lead V1/V2 (Fig. 1). The Brugada changes occur
argely in the early precordial leads because this overlies the
V, which harbors a more intense Ito current compared
ith the left ventricle.
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Year in Electrophysiology May 22, 2007:2061–9Arrhythmias are thought to be generated by phase 2
e-entry, a process initiated by voltage gradients from cells at
ifferent levels of depolarization (Fig 2). For example, cells
osing the action potential dome will be strongly negative
polarized) compared with more depolarized neighboring
ells (Fig. 2). It is thought that premature ventricular
omplexes caused by phase 2 re-entry serve as a trigger for
apid polymorphic ventricular arrhythmias.
alcium channel abnormalities and the Brugada syn-
rome. A very important new finding relates to the discov-
ry that mutant genes that encode for either the alpha
CACNAIC) or the beta (CACNB2) subunit of the Ca
hannel may result in a Brugada-like pattern (ST-segment
levation in V1 to V3) (6). These genes have been shown to
esult in significant loss of function of the Ca channel
ecause of separate genetic mutants encoding different
ubunits of the L-type Ca channel.
In addition, these mutant genes have been associated with
erious cardiac arrhythmias, and patients also tend to show
slightly shorter than normal QT interval. These findings
re important support both of the channelopathy concept
Figure 1 Pathogeneses of the Brugada Pattern
(A) A normal surface V2 recording together with endocardial (Endo), midmyocardia
transmural voltage gradient between epicardium and endocardium, giving rise to a
age changes producing a coved pattern in V2 (type I pattern). (D) Loss of the dom
ences between polarized and adjacent depolarized cells may lead to re-entry (phaselating to the Brugada pattern as well as of the pathogen- ssis of the cardiac rhythm disturbances. One previously
escribed abnormality in the L-type Ca channel was
escribed as the Timothy syndrome, which produces a
utation involving gain of function of the Ca channel
ia impaired inactivation of the channel.
otential drug remedy for the Brugada syndrome. An-
ther important observation from the Antzelevitch group
7) relates to use of agents to prevent the Brugada pattern
nd arrhythmias in simulated Brugada-type RV perfused
edge preparations. They found that dimethyl lithosper-
ate B (dmLSB), which is an extract of Danshen, a
hinese herbal remedy, eliminated the Brugada pattern in 3
eparate experimental models of the syndrome. They
howed that this agent augmented Na current active
uring phase 1 of the action potential. This agent is shown
o abolish the loss of the dome of the action potential, hence
liminating phase 2 re-entry as well as differences in
ransmural repolarization. In addition, they found that
mLSB did not prolong action potential duration or pro-
oke arrhythmias. These observations add to a growing list
f drugs that might ultimately be useful in treating the
nd epicardial (Epi) action potential (AP) recordings. (B) The development of a
eback configuration in V2 (type II Brugada pattern). (C) Further transmural volt-
e epicardial recording and enhanced coved pattern in V2. (E) Potential differ-
CG  electrocardiogram. Reprinted with permission from Antzelevitch (4).l (M), a
saddl
e in th
e 2). Eyndrome (4). Such drugs include quinidine, isoproterenol,
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May 22, 2007:2061–9 Year in Electrophysiologyhosphodiesterase inhibitors, and tedisamil. Drugs such as
uinidine and tedisamil block Ito current, whereas the other
rugs serve to augment Na and Ca currents during
hase I of the action potential.
ew clinical features of the Brugada syndrome. In addi-
ion, several important clinical features of the Brugada
yndrome were analyzed. The last consensus conference (8)
ocused on management of patients with the Brugada
yndrome and emphasized risk factors for sudden death in
erms of the spontaneous Brugada pattern (type I, right
undle branch block, and coved ST/T abnormalities) (Fig.
), history of sudden death in the family, as well as
ymptoms of syncope or aborted sudden death. In a recent
mportant prospective study of patients with the Brugada
yndrome, Veltmann et al. (9) pointed out the frequency of
CG changes between the different patterns in patients
ho had serial ECG recordings. Among 43 patients, only 1
Figure 2 Terfenadine Induces Brugada Phenotype More Readily
Each panel shows action potentials recorded from 2 epicardial sites and 1 endoca
obtained at a basic cycle length (BCL) of 2,000 ms, whereas terfenadine data wer
(A) Terfenadine (5 M)-induced, heterogeneous loss of action potential dome, ST-
preparation. (B) Terfenadine fails to induce Brugada phenotype in a female RV we
male preparation. (D) Incidence of phase 2 re-entry in male (6 of 7) versus female
Abbreviations as in Figure 1. Modified with permission from Antzelevitch (4).howed a consistent coved pattern, 15 patients initially showed a coved pattern, and 14 showed nondiagnostic
either saddleback pattern or nonspecific changes). On the
ther hand, of 28 patients who initially showed a nondiag-
ostic pattern, 8 developed a typical (type I) coved pattern
n follow-up. This important study emphasizes that if we
re going to use the type I ECG phenotype to assess risk,
ultiple ECG recordings are critical.
enetic basis for sinus node disease. Most of the genetic
tudies have focused on mutations associated with high risk
or sudden cardiac death. However, over the past year
everal studies have described the importance of genetic
utations in nonfatal arrhythmic syndromes. For example,
ilanesi et al. (10) described the genetic abnormality and
athogenetic mechanism explaining familial sinus bradycar-
ia. They found a large family cohort with sinus bradycardia
ith a genetic abnormality encoding HCN4 gene. This gene
ncodes the pacemaker current (If) that determines the
ale Than Female RV Wedge Preparations
ite, together with a transmural electrocardiogram. Control recordings were
rded at a BCL of 800 ms after a brief period of pacing at a BCL of 400 ms.
nt elevation, and phase 2 re-entry (arrow) in a male right ventricular (RV) wedge
eparation. (C) Polymorphic VT triggered by spontaneous phase 2 re-entry in a
7) RV wedge preparations when perfused with 5 M terfenadine for up to 2 h.in M
rdial s
e reco
segme
dge pr
(2 oflope of diastolic depolarization in sinus node cells (11). The
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Year in Electrophysiology May 22, 2007:2061–9f channels are encoded by the hyperpolarization-activated
yclic nucleotide (HCN) gated channel, and HCN4 is
ighly expressed in the mammalian sinus node.
Kinetic studies of the mutant channels showed that these
hannels were activated at more negative voltages and
eactivated faster than wild-type channels. Of interest was
he finding that the mutant channels were not affected by
yclic adenosine monophosphate activation of the channel.
he investigators found that these changes mimic those of
ow-dose acetylcholine. These important observations likely
ill teach us more about the pathogenesis of the sick sinus
yndrome, which is the most common reason for pacemaker
nsertion in the U.S.
ole of somatic mutations in patients with atrial fibril-
ation (AF). Another potentially important study was re-
orted by Gollob et al. (12) and focused on the role of
omatic mutations in the pathogenesis of AF. Connexin 40
s expressed selectively in atrial myocytes and is encoded by
he GJA5 gene. In this study, a total of 15 patients with AF
ere studied. The GJA5 gene was sequenced from deoxyri-
onucleic acid both in cardiac tissue as well as from
ymphocytes in peripheral blood. They found 4 missense
utations, 3 from cardiac tissue alone (somatic) and 1 from
oth cardiac tissue as well as lymphocytes (germ line). The
utant genes were studied to assess protein transport and
lectrical coupling between cells. The mutant proteins were
ound to impair intracellular transport or reduce intercellular
lectrical coupling. This fascinating observation raises a host
f issues. Could the somatic mutation be secondary to AF
ather than the primary event? If these observations are
onfirmed, it raises the issue of whether analyses of periph-
ral blood (without tissue analyses) are sufficient to discern
mportant genetic changes.
dvances in Catheter Ablation
trial tachycardia arising from the noncoronary aortic
alve cusp. We thought that the most exciting article
elating to catheter ablation was a study by Ouyang et al.
13), who described the clinical electrophysiological charac-
eristics and technique of ablation of focal atrial tachycardia
rising from the noncoronary cusp of the aortic valve. An
arlier case report by Tada et al. (14) described successful
blation from this site in 1 patient. Ouyang et al. extended
hese observations to 9 patients. In the 9 patients, the right
trium showed the earliest atrial activation site and was
lways associated with a bundle of His deflection. They
ound that atrial recordings from the noncoronary cusp of
he aortic valve preceded those from either the right or the
eft atrium and were not associated with a His bundle
eflection. The tachycardia was terminated within 8 s after
adiofrequency application, and none showed evidence of
trioventricular conduction prolongation. The investigators
lso provide beautiful anatomical drawings explaining the
emarkable results. This important study highlights the
mportance of mapping the noncoronary sinus for patients Oith focal atrial tachycardia (or accessory pathways) that are
arahisian. It is conceivable that such an approach may
bviate the need for potentially dangerous radiofrequency
pplications near the His bundle.
blation versus drug therapy for AF. There continues to
e a great deal of important studies relating to the role of
blative therapy for patients with AF. Jäis et al. (15)
resented data of 2 patient groups with documented symp-
omatic AF in whom at least one trial of antiarrhythmic
gents failed. They randomized 59 patients (who could
eceive up to 3 drugs) to the drug arm of the study and 53
atients to the ablation group. At 1 year, arrhythmia was
bsent in 75% of the ablation group compared with 7% of
he medical group. In addition, quality of life improved in
he ablation group. In this study, a mean of 1.8 procedures
ere required for the ablation group. This is a very exciting
omparative study but is limited by small numbers, short
ollow-up time, and need for almost 2 ablation sessions per
atient with a mean procedure time of 168 min. In addition,
onceivably failure of response to one drug might preselect
atients destined to have high failure rates to drug therapy.
ailored approaches for AF ablation. Further attention is
eing directed to so-called tailored approaches for ablative
ure of AF. A very interesting approach was reported from
äis et al. (16), in which the ablative lesion were staged using
oninducibility as an end point. The study included 74
atients with paroxysmal AF who were treated with a series
f staged procedures using AF noninducibility as an end
oint. Stage 1 was pulmonary vein isolation (PVI) alone,
nd stage 2 involved addition of a roof line or mitral isthmus
ine. If AF was still inducible, a second line (either roof or
itral isthmus) was added. They found that 42 patients
57%) became noninducible after PVI alone, a single line
esulted in noninducibility in an additional 20 patients, and
2 patients required 2 lines. On follow-up (18  4 months)
epeat procedures were required in 23 patients, and the
verall long-term efficacy was 91% (including repeat
rocedures).
This approach, however, differed from a tailored ap-
roach previously described by Oral et al. (17) for 100
atients with paroxysmal AF. In this approach, a wide area
blation surrounding the pulmonary vein together with roof
nd mitral isthmus line were performed. After this proce-
ure, 40% of patients were found to be noninducible for AF.
he remaining patients either had no further ablation or
ad ablations designed to ablate areas of fractionated po-
entials. At a 6-month follow-up, 86% of patients receiving
blation of fractioned potentials remained free of arrhyth-
ias, compared with 67% who remained inducible but did
ot receive further therapy. These kinds of studies are
mportant because they are designed to find the minimal
esion set required for arrhythmia cure. One of the negative
spects of using more lesion sets is the problem of left atrial
utter rhythms, which occurred in approximately 16% of
he patients in the Jäis et al. (16) study and in 23% of the
ral et al. (17) study.
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May 22, 2007:2061–9 Year in Electrophysiologyotors and fractionated potentials. There continues to be
nterest in use of endocardial mapping of localized rotors,
hich appear to drive AF. Haissaguerre et al. (18) studied
0 patients with AF who had undergone prior PVI and
inear ablation. Areas of dominant frequency were found in
8 (76%) of the studied patients. Local radiofrequency
blation resulted in either prolongation of the cycle length
r a terminated AF or a changed activation sequence to
nother rhythm. The investigators concluded that AF after
rior ablation seems to emerge from localized sources that
an be mapped and ablated.
In the same vein, a study by Kalifa et al. (19) evaluated
he mechanism of wave fractionation in the isolated sheep
eart. They found that the area of fractionated electrograms
ame not from the actual zone of dominant frequency (site
f anchored scroll wave) but instead from adjacent areas (3
m away). These were the areas showing most variability of
onduction velocity and fractionation. The investigators
uggest that a lesion target at the areas of maximal fraction-
tion should be extended to form a large obstacle so that the
merging wave front will be extinguished.
F and cardiac ganglionic plexus. There continues to be
n active interest in the role of the cardiac ganglionic plexus
n the pathogenesis of AF. All agree that activation of the
utonomic ganglia by either electrical stimulation (20) or
hemical stimulation (21) can provoke AF. Under active
nd lively debate is the possible clinical role of ganglion
lexus ablation. Pappone et al. (22) first called attention to
he beneficial role of ablation of vagal efferents. This has
een supported by the work of the Oklahoma group (23). In
ontrast, several studies have emphasized the problem of
omplete and long-term vagal denervation using current
echniques (24,25). These findings have provoked lively
nterchanges (26).
rugs
F and renin-angiotensin system inhibition. Although
o new antiarrhythmic drugs were approved in 2006, a
ariety of studies emphasize the growing importance of
onarrhythmic drug use for patients with cardiac arrhyth-
ias. For example, there continues to be great interest in the
ffects of inhibitors of the renin-angiotensin system in the
revention of AF.
Anand et al. (27) performed a meta-analysis of 9 ran-
omized clinical trials analyzing new onset of AF in patients
reated with either angiotensin-converting enzyme inhibi-
ors or angiotensin-receptor blockers. This study involved
2,469 patients followed for up to 5 years. In 5 trials that
xcluded patients with a history of AF, drug therapy was
ssociated with a reduction in risk of AF that was even
reater for those with heart failure. The investigators found
hat inhibition of the renin-angiotensin system reduces the
isk of AF by 18% across trials, with an even greater benefit
or those with heart failure (43%). This study nicely com-
lements prior experimental work showing that activation sf the renin-angiotensin system may be proarrhythmic
ither by direct electrophysiological effects or by enhance-
ent of atrial fibroses.
lopidogrel and aspirin for stroke prevention. Another
mportant study was reported by the ACTIVE (Atrial
ibrillation Clopidogrel Trial With Irbesartan for Preven-
ion of Vascular Events) writing group and summarized the
ffects of clopidogrel and aspirin versus oral anticoagulants
n stroke risk for patients with AF (ACTIVE W) trials
28). In this study, patients with AF and one or more risk
actors for stroke were randomized to oral anticoagulation
herapy with a target international normalized ratio of 2 to
U) versus clopidogrel 75 mg/day and aspirin 75 to 100
g/day. There were 3,371 patients randomized to the
nticoagulation group and 3,335 patients to the clopidogrel/
spirin group. The study end points were stroke, other
ystemic embolic events, myocardial infarction, or vascular
eaths. The study was discontinued prematurely because of
significant increase of vascular events in the clopidogrel/
spirin arm. The annualized risk for the clopidogrel/aspirin
roup was 5.6%, versus 3.93% for the group treated with
ral anticoagulants. This important study showed the supe-
iority of antithrombin therapy and emphasizes the need for
uch therapy in patients with AF.
holesterol lowering in patients with defibrillators. An-
ther contribution on the use of nonarrhythmic drugs for
atients with cardiac arrhythmia was the CLARIDI (Cho-
esterol Lowering and Arrhythmia Recurrences After Inter-
al Defibrillator Implantation) trial, which was presented at
he Heart Rhythm Society (HRS) meetings (29). The study
as composed of 106 patients with coronary artery disease
nd ventricular arrhythmias treated with an automatic
mplantable cardioverter-defibrillator (AICD). The groups
ad a mean ejection fraction of 39% and 45% (not signifi-
ant), and all patients had congestive heart failure. These
atients were randomized to 80 mg/day of atorvastatin or
lacebo. The atorvastatin group showed an almost 50%
eduction of ICD intervention (from 38% to 21%) over a
ollow-up of 1 year. In the atorvastatin group, the low-
ensity lipoprotein cholesterol decreased from 130 mg/dl to
5 mg/dl, and low-density lipoprotein levels were un-
hanged for the placebo group. Prior reports have docu-
ented the efficacy of statin therapy for prevention of AF;
his report supports prior retrospective studies of statin
herapy for those with ventricular arrhythmias.
evices
ICDs and pacemakers. In 2006 there were no pivotal
tudies that would redefine or expand the use of device
herapy in clinical practice. Most of the published works
nvolved re-analysis of data from previous published seminal
rials to refine ICD use and risk stratification. The run of
evice recalls and safety alerts in 2005 has practically
isappeared in 2006. With that, news media coverage and
crutiny of the device industry and of our relationships with
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Year in Electrophysiology May 22, 2007:2061–9anufacturers also have subsided. New recommendations
n device performance policies and guidelines have been
ublished by the HRS. The projected increase in device
mplantation and sales never materialized. In this part of the
eview, we examine how some of the published works may
ffect our approach to device implantation and clinical
ractice. We also examine a brewing controversy that may
ead to abandonment of the traditional RV apical pacing
ite. Finally, we explore reasons for the relatively flat ICD
nsertion rate in 2006.
RS device performance policies and guidelines. In
esponse to the recent device recalls and safety alerts, an
RS task force presented recommendations to the industry,
.S. Food and Drug Administration, and physicians on
evice performance policies and guidelines (30). In sum-
ary, for the physicians, we are urged to return all explanted
evices (including those retrieved postmortem) to the man-
facturers for analysis, use a standardized Physician Device
dvisory Notification format to assist assessment and char-
cterization of a device advisory, participate in the National
ardiovascular Data Registry ICD registry, consider the
isks and benefits of device replacement and alternatives in
atients with an affected device, and communicate to
atients device benefits and expected device performance—
ncluding rate of unexpected and unpredicted component
ailure. The industry is urged to adopt standard reporting of
evice performance, establish an independent advisory com-
ittee to determine the threshold for action, develop a
tandardized Physician Device Advisory Notification for-
at, and develop wireless and remote monitoring technol-
gies. The task force effort surely will improve tracking of
evice performance and management of recalls and safety
lerts by all stakeholders. It is noteworthy that the physi-
ians were not specifically asked to incorporate into their
ractices the remote device surveillance technologies that
he industry was urged to develop. This is important because
he panel recognized the limitations of the current voluntary
eporting system. These systems (Manufacturer and User
acility Device Experience Database and the National
ardiovascular Data Registry ICD Registry) were not
esigned to perform surveillance of device function. How-
ver, wireless remote monitoring by automatically up-
oading extensive device performance data at defined
ntervals provides an excellent data repository for post-
arket surveillance.
CD Use
election of patients. In a provocative article, Stevenson
nd Desai (31) essentially challenged physician use of ICDs
nd the selection of appropriate heart failure patients who
ill benefit from primary reduction of sudden death. The
nvestigators perceived that most ICD users do not follow
he American College of Cardiology/American Heart As-
ociation guidelines. One of the investigators’ main conten-
ions is that because the benefit of an ICD is not seen until rfter the first year after implantation, patients with frequent
ospitalizations, a systolic blood pressure below 90 mm Hg,
ncreasing creatinine levels, an inability to administer
ngiotensin-converting enzyme inhibitors, or an inability to
alk 2 blocks should not receive an ICD because they are
nlikely to survive 2 years with a good quality of life and to
eap the benefit of ICD therapy. The investigators also
iscussed the following points: 1) The risk of sudden cardiac
eath has diminished even in the absence of an ICD, and
nly 21% of all death were considered unexpected (with
50% in class III patients). 2) Successful shocks for
entricular tachycardia (VT) and ventricular fibrillation
VF) were associated with more than a 3-fold increase in
ortality in the first year. 3) Serious ICD complications
infection and hardware problems, including manufacturer
ecalls and safety alerts) occurred in 4% to 15% of patients.
) With prevention of sudden death by ICDs, the patients
ould “survive to suffer from crippling symptoms of end-
tage hemodynamic decompensation.” 5) The patients were
ot probably informed of the “real” benefits of ICD therapy
the investigators preferred “the glass is half-empty” ap-
roach). Although the investigators raised some very im-
ortant, provocative, and challenging observations and ar-
uments directed toward ICD users, they should not be
nterpreted by health care providers and referring physicians
s a “call to disarm.” There is no solid evidence showing that
mplanting physicians are overtly deviating from the im-
lantation guidelines. Prevention of sudden death that may
therwise occur in 20% to 50% of heart failure patients is
ighly rewarding. As pointed out in the accompanying
ditorial, the ensuing adverse prognosis after successful
evice therapy clearly should not be a deterrent to ICD
nsertion (32).
iming of ICD insertion. The Centers for Medicare and
edicaid Services (CMS) coverage policy for ICD insertion
n patients with cardiomyopathy for primary prevention
tipulates that the patients must not have had revascular-
zation (coronary artery bypass graft or percutaneous coro-
ary intervention) within past 3 months. Some clinicians are
oncerned that life-threatening arrhythmia events may oc-
ur during the 3-month waiting period. A re-analysis of 951
atients in the MADIT-II (Multicenter Automatic Defi-
rillator Implantation Trial II) trial who underwent coro-
ary revascularization showed that patients who received
CD insertion more than 6 months after revascularization
ad a significant survival benefit from ICD, whereas pa-
ients who received an ICD 6 months or less after revascu-
arization experienced none (33).
This is because the risk of sudden cardiac death is
elatively low early after revascularization. The result is
onsistent with the initial published observation that the
urvival benefit of ICD in the MADIT-II trial was not seen
ntil 1 year after implantation. This retrospective study
rovides strong evidence showing that ICD insertion safely
an be deferred for at least 6 months after coronary
evascularization in MADIT-II type patients. The timing
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May 22, 2007:2061–9 Year in Electrophysiologyf ICD insertion was also examined in patients from the
EFINITE (Defibrillators in Nonischemic Cardiomyopa-
hy Treatment Evaluation) trial (34). The conclusion is that
he time from initial diagnosis of nonischemic cardiomyop-
thy patients to insertion of ICD (3 or 9 months) does not
hange the benefit as long as a reversible cause of left
entricular dysfunction is excluded. This post hoc analysis
uestions the validity of the CMS limiting ICD insertion in
onischemic cardiomyopathy to 9 months after initial di-
gnosis. However, as pointed out by the accompanying
ditorial, the key issue is identifying the potential for
eversibility. There are many instances of marked improve-
ent of left ventricular systolic function in response to
edical treatment or lifestyle modification. Identification of
rognosticating markers will greatly enhance our ability to
etter utilize ICD therapy and to further refine our timing
indow for ICD insertion.
lectrophysiology expertise and ICD management. The
fforts of device industry and the HRS to expand the pool of
CD users by recruiting and training nonelectrophysiolo-
ists have not been uniformly embraced. One of the major
bjections is that general cardiologists or surgeons lack the
xpertise for device programming, which may lead to
nappropriate arrhythmia detection and therapy. The EM-
IRIC (Comparison of Empiric to Physician-Tailored
rogramming of Implantable Cardioverter Defibrillators)
rial was designed to address this important health care
elivery issue (35). Nine hundred patients who received a
ual-chamber ICD for either primary or secondary preven-
ion were enrolled in the study. The EMPIRIC arm used
reset programmed detection and treatment parameters (3
etection zones: 250, 200, and 150 beats/min; shock only
or the VF zone, and antitachycardia pacing, adenosine
riphosphate, and shock for the VT zones), whereas the
mplanting electrophysiologists determined the program-
ing parameters in the physician-tailored (TAILORED)
rm. The primary end point was the appropriateness of
hocks for VT/VF. When compared with the TAILORED
rm, the EMPIRIC arm devices had a higher number of
eats to VF detection, were more frequently set to detect
nd treat slower tachycardias, had more supraventricular
achycardia discriminators, and used more adenosine
riphosphate therapy and delivered higher first shock en-
rgy. The percentage of both VT/VF and supraventricular
achycardia episodes that resulted in a shock and the overall
ortality rate in the EMPIRIC arm were “noninferior”
defined as no greater than 10% higher in the EMPIRIC
rm) in comparison with the TAILORED arm. There was
o difference in emergency room visits or unscheduled
utpatient visits; the EMPIRIC arm had significantly
ewer unscheduled hospitalizations. The EMPIRIC arm
ad a significantly smaller number of VT episodes treated
ith shocks and a significantly lower percentage of inap-
ropriate shocks for supraventricular tachycardia. The study
esults provide very compelling evidence showing that a
trategy of empiric ICD programming for VT/VF detection nnd therapy is at least as effective as tailored programming
y electrophysiologists.
-wave alternans in risk stratification. One of the most
mportant areas of investigation is delineation of risk strat-
fication so that ICD therapy is used more appropriately. A
umber of recent articles strongly suggested that the micro-
olt T-wave alternans (MTWA) test is an independent
redictor of mortality in patients with ischemic cardiomy-
pathy and allows us to better stratify patients at risk for
udden cardiac death, thereby improving our selection of
atients for ICD insertion (36–38). The investigators of the
BCD (Alternans Before Cardioverter Defibrillator) trial
ecently reported that the MTWA test was as effective as
lectrophysiologic studies in predicting ventricular arrhyth-
ia events at 1 year among patients with ischemic cardio-
yopathy (39). Although we are still awaiting full publica-
ion of this and other trials, the negative predictive value of
he MTWA test is probably near 96%, making it a poten-
ially valuable tool in screening out patients who are less
ikely to benefit from ICD insertion.
It is important to note that the MTWA test becomes less
redictive after about 12 to 15 months; periodic retesting
ay have been required. In March 2006, the CMS provided
edicare reimbursement for use of the MTWA test for risk
tratification.
iventricular pacing versus RV apical pacing. Even as we
re well into the fifth decade of pacing for bradycardia, the
ontroversy over single- versus dual-chamber (AV) pacing
40) has been replaced with one pitting RV pacing against
iventricular pacing. A number of editorial comments and
eviews appeared in 2006 addressing this controversy (40–
3). Prompted by the result of the DAVID (Dual Chamber
nd VVI Implantable Defibrillator) trial (44), many inves-
igators began to look for a deleterious effect of left
entricular activation delay caused by RV apical pacing,
specially in the presence of abnormal QRS duration and
entricular systolic dysfunction. A number of studies and
eviews decrying the harmful effects of RV apical pacing
ave appeared (45–47). These deleterious effects include left
entricular dysfunction, altered cardiac histology by biopsy,
igher degree of intraventricular dyssynchrony, left ventric-
lar remodeling, dilatation, hypertrophy, lower cardiac out-
ut and exercise performance, presence of regional myocar-
ial perfusion, and wall motion abnormality in the absence
f coronary artery disease (42). Most of the studies were
bservational or represent retrospective subgroup analysis of
ata initially collected for an entirely different study purpose
48). The very few randomized studies involved either a very
mall number of patients or a short follow-up period (49).
any reported improvements in selected parameters with
iventricular pacing have not been shown and have
ot translated to any significant long-term clinical
mprovements.
Fifty years of pacing experience strongly indicates thatot in every patient does RV pacing develop into left
v
a
u
i
b
i
p
t
t
s
c
h
e
p
t
(
d
a
p
m
T
(
a
p
a
I
c
c
a
r
p
p
f
e
o
p
p
t
t
p
I
l
p
P
A
m
m
d
c
I
s
r
R
m
A
s
R
1
1
1
1
1
1
1
1
1
1
2068 Scheinman and Keung JACC Vol. 49, No. 20, 2007
Year in Electrophysiology May 22, 2007:2061–9entricular dyssynchrony and heart failure. It is also reason-
ble to assume that many pacemaker patients are not
ndergoing ventricular pacing all of the time. It is therefore
nconceivable, from both a clinical practice and a cost-
enefit standpoint, to implant a biventricular pacing system
n all patients to prevent heart failure induced by RV apical
acing in a very small number of patients—even if biven-
ricular pacing would prevent heart failure in every suscep-
ible patient.
Biventricular pacing, despite recent advances in coronary
inus lead delivery systems, remains a major technical
hallenge for many users and is associated with a much
igher incidence of complications. At present, the best
vidence in favor of biventricular pacing is limited to
atients with AF, especially those with reduced LV func-
ion, who undergo AV junctional ablation for rate control
49,50).
In view of the demand on our technical skills and health
ollars, a better way to avoid deleterious effects from RV
pical pacing is to minimize pacing by paying attention to
rogramming of the devices and by selecting devices with
echanisms that promote intrinsic AV conduction.
he state of ICD implants. The MADIT-II and SCD-HeFT
Sudden Cardiac Death in Heart Failure Trial) results led to
n expansion of indications for ICD insertion for primary
revention of sudden cardiac death. The industry projected
20% revenue growth that never materialized in 2006.
ndeed, the ICD market has declined. Device recalls, loss of
onsumer confidence (both patients and referring physi-
ians), and reimbursement constraints have been identified
s possible causes of the decline. Furthermore, there was no
ecent publication of a pivotal clinical trial, which often had
rovided an impetus for device implantation. Referring
hysicians may now be more selective in referring patients
or ICD insertion, and more consideration is being paid to
xisting comorbidities and functional status that may negate
r reduce ICD survival benefit, especially in heart failure
atients. This contributes to a decrease in the size of the
rophylactic ICD prevalence pool. Newer risk stratification
ools may or may not increase the number of ICD uses. On
he one hand, application of these tools may identify
atients who are at low risk and therefore do not need an
CD. On the other hand, application of these tools to a
arger pool of patients may identify high-risk patients and
rovide more convincing evidence for ICD referral.
ractice guidelines and expert committee reports.
chievements in understanding and advances in the treat-
ent warrant changes both in the evaluation and manage-
ent of patients with or at risk for arrhythmias and also in
efinitions and standards of performance. In 2006 several
ommittee-generated consensus documents were published.
n addition to recommendations that represent the consen-
us of experts, these documents are valuable sources of
eferences. Most are available online at acc.org (30,51–54).eprint requests and correspondence: Dr. Melvin M. Schein-
an, University of California San Francisco, 500 Parnassus
venue, Box 1354, San Francisco, California 94143. E-mail:
cheinman@medicine.ucsf.edu.
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